Lyka Labs Limited

NSE LYKALABS.NS

Lyka Labs Limited Net Cash Used For Investing Activities for the year ending March 31, 2024: USD -1.14 M

Lyka Labs Limited Net Cash Used For Investing Activities is USD -1.14 M for the year ending March 31, 2024, a -227.19% change year over year. Net cash used for investing activities is total cash inflows and outflows related to activities intended to generate future income and cash flows from investments.
  • Lyka Labs Limited Net Cash Used For Investing Activities for the year ending March 31, 2023 was USD 894.32 K, a 210.02% change year over year.
  • Lyka Labs Limited Net Cash Used For Investing Activities for the year ending March 31, 2022 was USD -812.84 K, a -3,589.90% change year over year.
  • Lyka Labs Limited Net Cash Used For Investing Activities for the year ending March 31, 2021 was USD -22.03 K, a -51.60% change year over year.
  • Lyka Labs Limited Net Cash Used For Investing Activities for the year ending March 31, 2020 was USD -14.53 K, a 97.46% change year over year.
Key data
Date Net Cash Used For Investing Activities Net Cash Used Provided By Financing Activities Dividends Paid Capital Expenditure
Market news
Loading...
SV Wall Street
NSE: LYKALABS.NS

Lyka Labs Limited

CEO Mr. Kunal Narendra Gandhi
IPO Date Jan. 1, 1996
Location India
Headquarters Spencer Building
Employees 423
Sector Health Care
Industries
Description

Lyka Labs Limited, a pharmaceutical company, engages in development, manufacture, and marketing of pharmaceutical formulations and active pharmaceutical ingredients across various therapeutic segments in India. The company manufactures and sells various formulations, including emollient, topical steroid, antifungal agent, topical anti-bacterial, acne management, dermatological formulation, pain killer, anti-aging, cleansing lotion, hair care, anti-dandruff shampoo, sunscreen, anti-acne, cosmeceutical, anti-oxidant, proton pump inhibitor, anti-malarial, anti-bacterial, corticosteroid hormones, cephalosporin, dry powder injection, muscle relaxant, bone resorption inhibitor, anti-oxidant/liver disease, antibiotic, and lyophilized products. It also offers contracted manufacturing services to various large pharmaceutical companies; and medical and technical assistance in the areas of manufacturing know how and manufacturing facilities, as well as technical data, such as molecule stability testing data, impurity profile, and BA/BE clinical study data. In addition, it provides products and services in therapeutic categories, such as intensive care, gastroenterology, anti-infective, anti-fungal, surgery care, cosmetologist, urology, wound care, and anesthesia, as well as deals in pharmaceutical products. The company offers its products in various formulations, including injections, creams, ointments, gels, and lotions. It also exports its products to Bangladesh, Combodia, Congo, Costa Rica, Peru, Romania, Russia, Sri Lanka, Sudan, Ukraine, Venezuela, and Vietnam. Lyka Labs Limited was incorporated in 1976 and is based in Mumbai, India.

Similar companies

KOPRAN.NS

Kopran Limited

USD 2.16

-0.74%

MANGALAM.NS

Mangalam Drugs & Organics Limited

USD 1.19

-0.78%

NECLIFE.NS

Nectar Lifesciences Limited

USD 0.37

-5.05%

MARALOVER.NS

Maral Overseas Limited

USD 0.92

-1.52%

GUFICBIO.NS

Gufic Biosciences Limited

USD 4.86

-0.15%

StockViz Staff

February 1, 2025

Any question? Send us an email